Skip to content

Outcomes of Combined Cataract Surgery With Retinal Surgery for Visually Significant Epiretinal Membrane With Vivity Versus Monofocal Intraocular Lens

Outcomes of Combined Cataract Surgery With Retinal Surgery for Visually Significant Epiretinal Membrane With Vivity Versus Monofocal Intraocular Lens

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07070492
Enrollment
36
Registered
2025-07-17
Start date
2025-07-31
Completion date
2027-07-31
Last updated
2025-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract and IOL Surgery, Epi-retinal Membrane

Brief summary

To investigate the patient Quality of Life and satisfaction outcomes of combined cataract surgery with retinal surgery for visually significant epiretinal membrane in patients receiving Vivity IOL versus standard monofocal controls.

Detailed description

The information gained by this study will help understand better the suitability of Vivity IOLs for patients with a common retinal condition and potentially expand access and offering of premium IOLs to help patients gain independence from glasses, which can improve quality of life.

Interventions

DEVICEcataract surgery

cataract surgery receiving Vivity IOL or standard mono focal controls

PROCEDUREretinal surgery

Retinal surgery for visually significant epiretinal membrane

Sponsors

Debbie Kuo, MD
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients with visually significant epiretinal membrane who are undergoing or have already had pars plana vitrectomy and membrane peel combined with cataract surgery using Clareon Vivity and Clareon Vivity Toric IOLs or monofocal IOL * IOL powers between +6D to +30.0D, T3-T6

Exclusion criteria

* History of ocular or refractive surgery * Other ocular or systemic comorbidities that may alter or reduce visual acuity and contrast sensitivity, such as severe dry eye/ocular surface disease, glaucoma, macular degeneration, retinopathy, neuro-ophthalmic diseases, strabismus/amblyopia etc. * Patients with irregular astigmatism, corneal dystrophies, pupil abnormalities, zonular laxity * Intraoperative or postoperative complications

Design outcomes

Primary

MeasureTime frame
Vision AcuityAt the study visit at least 3 months after the combined cataract and retinal surgeries

Secondary

MeasureTime frameDescription
Contrast SensitivityAt the study visit at least 3 months after the combined cataract and retinal surgeries
Patient Reported Outcomes (PRO) on vision-related Quality of Life (QOL) and satisfactionAt the study visit at least 3 months after the combined cataract and retinal surgeriesUsing 5-point Likert scale, Research Insight's Validated PRO Questionnaire to assess patient overall satisfaction post-surgery, QOL on driving, reading, computer use, watching TV, sports, and Glare/Haloes.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026